Publications by authors named "T Toshima"
Introduction: Malignant melanomas occur most commonly in the skin, mucous membranes, or choroid. Clitoral malignant melanomas are extremely rare. Stage IV malignant melanomas have a poor prognosis, and molecularly targeted agents or immune checkpoint inhibitors are recommended.
View Article and Find Full Text PDFArticle Synopsis
- * The study identified a protein called SHARPIN, located on an amplified chromosome in CRC, which is overexpressed in tumor cells and linked to poor patient prognosis due to its influence on lymphatic invasion.
- * SHARPIN affects the progression of CRC by regulating the proteins MDM2 and p53, leading to changes in cell cycle and apoptosis, thus presenting SHARPIN as a potential new target for therapeutic interventions in colorectal cancer.
Article Synopsis
- New diagnostic criteria have classified small-for-size syndrome (SFSS) after living donor liver transplantation into three severity groups, and this study focuses on grade A SFSS and its mortality risk.
- Data from 406 patients were analyzed, categorizing them into up-trend, down-trend, and ascites groups based on their bilirubin levels and ascites presence after surgery.
- While survival rates were similar for SFSS and non-SFSS patients, those in the up-trend group had significantly higher 90-day mortality and should receive aggressive intervention if they have additional risk factors.
Purpose: To validate the reliability of fibrosis markers as predictors of graft survival in living donor liver transplantation (LDLT) recipients.
Methods: We reviewed data retrospectively, from 163 patients who underwent adult LDLT with preoperative measurements of type IV collagen (CIV), Mac-2 binding protein glycosylation isomer (M2BPGi), and hyaluronic acid (HA). Patients were divided into high and low groups for each biomarker, based on optimal cutoff values, and graft loss within 6 months was evaluated in each group.
Aim: Reactivation of hepatitis B virus (HBV) after liver transplantation (LT) remains a problem; thus, development of more effective HBV reactivation prophylaxis is desirable. We evaluated the efficacy of a combination of a long-term nucleotide analog (NA), such as entecavir (ETV) or tenofovir alafenamide (TAF), and short-term hepatitis B immunoglobulin (HBIG) in preventing HBV reactivation and compared it with conventional HBV prophylaxis.
Methods: Between February 1999 and August 2023, 135 patients underwent living-donor liver transplantation for liver cirrhosis or acute liver failure caused by HBV infection or received an LT from a hepatitis B core antibody-positive donor.